Results 121 to 130 of about 41,188 (289)

Myelodysplastic/Myeloproliferative Neoplasms with Features Intermediate between Primary Myelofibrosis and Chronic Myelomonocytic Leukemia: Case Series and Review of the Entity

Hemato
Diagnosis of myeloid neoplasm is currently performed according to the presence of a predetermined set of clinical, morphological, and molecular diagnostic criteria agreed upon by a consensus of experts.
Arturo Bonometti, Simone Zanella, Daoud Rahal, Chiara Milanesi, Rossella Caselli, Matteo Giovanni Della Porta, Silvia Uccella, Sara Fraticelli   +7 more
doaj   +1 more source

P572: VENETOCLAX AND HYPOMETHYLATING AGENT COMBINATIONS FOR THE TREATMENT OF ADVANCED MYELOPROLIFERATIVE NEOPLASMS AND ACUTE MYELOID LEUKEMIA WITH EXTRAMEDULLARY DISEASE

, 2022
K. Sanber, Kai Ye, H.-L. Tsai, Michelle G. Newman, Alex J Ambinder, A. DeZern, T. Jain   +6 more
openalex   +1 more source

Brief update on systemic therapies in myeloproliferative neoplasms [PDF]

, 2023
Janine Steichen, Dominik Wolf‎
openalex   +1 more source

Non‐T‐Depleted Haploidentical Transplantation Compared to Allogeneic Transplantation From Matched Siblings or Unrelated Donors in Patients With Secondary AML in First Complete Remission: A Study From the ALWP/EBMT

American Journal of Hematology, Volume 101, Issue 2, Page 281-290, February 2026.
ABSTRACT Allogeneic hematopoietic stem cell transplantation (HSCT) is a curative option for secondary acute myeloid leukemia (sAML). This study compared haploidentical donor (Haplo), matched sibling donor (MSD), and matched unrelated donor (MUD) HSCT in patients with sAML in first complete remission (CR1).
Arnon Nagler, Sarah Kayser, Allain Thibeault Ferhat, Nicolaus Kröger, Matthias Eder, Gérard Socié, Didier Blaise, Thomas Schroeder, Hélène Labussière‐Wallet, Johan Maertens, Alessandro Busca, Edouard Forcade, Tobias Gedde‐Dahl, Alessandro Rambaldi, Claude Eric Bulabois, Gesine Bug, Ali Bazarbachi, Eolia Brissot, Bipin Savani, Mohamad Mohty, Fabio Ciceri   +20 more
wiley   +1 more source

Myeloproliferative neoplasms

HemaSphere, 2019
Hussein Hamad, Gustavo Rivero
openaire   +4 more sources

Vaping‐Induced Erythrocytosis Resolved With Cessation of e‐Cigarette Use

Clinical Case Reports, Volume 14, Issue 2, February 2026.
ABSTRACT Vaping use is a global health concern with multiple adverse general health effects. We report a young man with vaping‐induced erythrocytosis that resolved following cessation of e‐cigarette use. Presence of erythrocytosis without a history of hypoxia or associated medications should prompt a thorough investigation for secondary causes ...
Jenyvette Hsia, Ella Derkzen, William Reisman, Benjamin Chin‐Yee, Cyrus C. Hsia   +4 more
wiley   +1 more source

Glucose‐6‐phosphate dehydrogenase deficiency is associated with improved survival in patients with acute myeloid leukemia treated with venetoclax and azacitidine

Cancer, Volume 132, Issue 3, 1 February 2026.
Abstract Background Glucose‐6‐phosphate dehydrogenase (G6PD) deficiency impairs cellular redox balance through reduced NADPH production and is the most common enzymatic disorder‐causing anemia. Venetoclax combined with azacitidine (Ven‐Aza) targets leukemic stem cells by disrupting oxidative phosphorylation and inducing mitochondrial stress. This study
Shira Buchrits, Alon Rozental, Noa Korngold, Ofer Algor, Shirly Partouche, Galit Granot, Pia Raanani, Ofir Wolach   +7 more
wiley   +1 more source

Prognostic value of flow cytometry in myelodysplastic neoplasms (MDS): Composition of a FCM‐prognostic score (FCM‐PS) for overall survival

HemaSphere, Volume 10, Issue 2, February 2026.
Abstract Flow cytometry (FCM) is a co‐criterion in myelodysplastic neoplasms (MDS) diagnostics, currently not used for prognostication. This study aimed to develop an FCM‐score predicting overall survival (OS) in MDS to improve early clinical patient prognostication.
Aida Santaolalla, Uta Oelschlaegel, Susann Winter, Shirin Jamshidi, Theresia M. Westers, Katja Sockel, Martin Bornhäuser, Rosa Andres Ejarque, Farzin Farzaneh, Antonella Poloni, Anne‐Sophie Kubasch, Mieke Van Hemelrijck, Arjan A. van de Loosdrecht, Uwe Platzbecker, Shahram Kordasti   +14 more
wiley   +1 more source

The molecular management of classic myeloproliferative neoplasm

Journal of the Egyptian National Cancer Institute
Background Whole-genome sequencing has enabled the development of a wide range of analytical tools to search for abnormalities associated with tumors. As classic myeloproliferative neoplasms (MPNs) are associated with genomic alterations in hematopoietic
Charlène G. S. Soro, Sara Benchikh, Adil El Hamouchi, Imane Morjane, Rachid Saile, Halima Lebrazi, Sanaa Nassereddine   +6 more
doaj   +1 more source

The association of bladder myeloid sarcoma and unclassified myelodysplastic/myeloproliferative disease [PDF]

, 2009
Myeloid sarcoma of the urinary bladder is a rare disorder. We report a 71-year-old man with hematuria who had a diffuse myeloid sarcoma of the bladder.
Bircan Sönmez, Mehmet Sönmez, Rasin Özyavuz, Sevdagül Mungan, Ümit Çobanoğlu   +4 more
core